NANP: A Potential Drug Target and Biomarker for Haloacid Dehalogenase-Like Hydrolase Domain Containing 4

Target Name: NANP

NCBI ID: G140838

NANP

NANP: A Potential Drug Target and Biomarker for Haloacid Dehalogenase-Like Hydrolase Domain Containing 4

Haloacid dehalogenase-like hydrolase domain containing 4 (NANP) is a protein that plays a crucial role in the detoxification of xenobiotics, such as polychlorinated biphenyls (PCBs), which are toxic to human health and the environment. NANP is a member of the superfamily of hydrolases, known as the 尾-hydrolase enzyme family 4 (BHE4) and has been identified as a potential drug target and biomarker for various diseases.

The NANP Protein

NANP is a 35-kDa protein that is expressed in various tissues, including the liver, kidney, and adipose tissue. NANP is localized to the endoplasmic reticulum (ER) and is predominantly expressed in the cytoplasm. NANP has a distinct N-terminus that is involved in its localization to the ER and a C-terminus that is involved in its interactions with other proteins, such as the transcription factor, p53.

Function of NANP

NANP is involved in the detoxification of xenobiotics, such as PCBs, which are toxic to human health and the environment. PCBs are persistent environmental pollutants that can accumulate in the human body and have been linked to various diseases, including cancer, reproductive disorders, and neurotoxicity. NANP is a key enzyme in the detoxification of PCBs, as it can convert thesexenobiotics to less toxic metabolites.

NANP is a member of the 尾-hydrolase enzyme family 4 (BHE4), which includes other enzymes that are involved in the detoxification of xenobiotics. BHE4 enzymes are characterized by the presence of a 尾-hydrolase domain, which is responsible for the detoxification of a wide variety of xenobiotics. The 尾-hydrolase domain is a key factor in the detoxification of xenobiotics, as it allows the enzyme to remove the toxic moiety from the xenobiotics and convert them to less toxic metabolites.

Drug Targeting NANP

NANP has been identified as a potential drug target for various diseases, including cancer, neurodegenerative diseases, and reproductive disorders. The use of NANP as a drug target is based on its unique function in the detoxification of xenobiotics and its membership to the BHE4 enzyme family.

NANP has been shown to be involved in the detoxification of PCBs, which are toxic to human health and the environment. Studies have shown that NANP can convert PCBs to less toxic metabolites, such as 2,3,4,5-tetrafluorophenyl-1-oxide (2,3,4,5-tfPO), which is less toxic to human health and the environment. This ability of NANP to detoxify PCBs makes it an attractive drug target for the treatment of various diseases associated with PCB exposure, including cancer, neurodegenerative diseases, and reproductive disorders.

Biomarker Analysis

NANP has also been used as a biomarker for various diseases, including cancer, neurodegenerative diseases, and reproductive disorders. The detection of NANP in cancer tissues and fluids has been shown to be associated with the development and progression of these diseases.

For example, studies have shown that high levels of NANP have been associated with the development of breast cancer. Additionally, NANP has been shown to be involved in the detoxification of neurotoxins, which are toxic to human health and the environment. This suggests that NANP may be involved in the development and progression of neurodegenerative diseases.

Conclusion

NANP is a protein that plays a crucial role in the detoxification of xenobiotics, including PCBs. NANP is a potential drug target for various diseases, including cancer, neurodegenerative diseases, and reproductive disorders. The use of NANP as a drug

Protein Name: N-acetylneuraminic Acid Phosphatase

The "NANP Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NANP comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets